Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 3/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662980 | 0.85 | NOTUM (0.50) | NOTUMNPSR1ALOX15 | |
| SCHEMBL25884344 | 0.84 | NOTUM (0.49) | NOTUMNPSR1ALOX15GLS | |
| SCHEMBL27015707 | 0.84 | TGM2 (0.37) | NOTUMFNTAFNTB | |
| SCHEMBL15257810 | 0.82 | CA1 (0.54) | — | |
| SCHEMBL24256389 | 0.81 | NOTUM (0.47) | NOTUMNPSR1ALOX15 | |
| SCHEMBL25882774 | 0.81 | NOTUM (0.47) | NOTUMNPSR1ALOX15GLS | |
| SCHEMBL24812463 | 0.80 | GBA1 (0.53) | NOTUMGLS | |
| SCHEMBL15257804 | 0.80 | CA12 (0.36) | NOTUMFNTAFNTB | |
| SCHEMBL18235987 | 0.80 | POLB (0.38) | NOTUM | |
| SCHEMBL29324043 | 0.79 | NOTUM (0.45) | NOTUMNPSR1ALOX15GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2009141240-A1 | NOVEL DUAL TARGETING ANTITUMOURAL CONJUGATES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | MAGT1, GALNT1, NMT1 | NOTUM 483/4885NPSR1 4211/4885ALOX15 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.